A number of stocks jumped in the afternoon session after the major indices rebounded, as Fed Chair Jerome Powell delivered dovish remarks at the much-awaited Jackson Hole symposium. Powell suggested that with inflation risks moderating and unemployment remaining low, the Federal Reserve might consider a shift in its monetary policy stance, including potential interest rate cuts. This outlook eased market concerns about prolonged high interest rates and their impact on economic growth. The prospect of lower borrowing costs bolstered investor confidence, particularly in sectors that have lagged, leading to a broad rally across the market.
Globus Medical (GMED) exemplifies Affordable Growth investing with strong revenue/earnings growth, reasonable valuation, and solid profitability—ideal for GARP-focused investors.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Medical device company Globus Medical (NYSE:GMED) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 18.4% year on year to $745.3 million. The company expects the full year’s revenue to be around $2.85 billion, close to analysts’ estimates. Its non-GAAP profit of $0.86 per share was 14.1% above analysts’ consensus estimates.
Shares of medical device company Globus Medical (NYSE:GMED)
jumped 5.1% in the morning session after the company reported strong second-quarter financial results that surpassed Wall Street's expectations for both revenue and profit. The medical device company announced second-quarter worldwide net sales of $745.3 million, an 18.4% increase year-over-year, which topped analyst forecasts. Adjusted earnings per share landed at $0.86, comfortably beating the consensus estimate of $0.75. The results were supported by the ongoing integration of its 2023 acquisition of NuVasive, which expanded the company's global reach and product offerings in the spine technology market. Looking forward, Globus Medical reaffirmed its full-year 2025 guidance, projecting revenue around $2.85 billion and adjusted earnings per share of approximately $3.15, signaling confidence in its outlook.
Medical device company Globus Medical (NYSE:GMED) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 18.4% year on year to $745.3 million. The company expects the full year’s revenue to be around $2.85 billion, close to analysts’ estimates. Its non-GAAP profit of $0.86 per share was 14.1% above analysts’ consensus estimates.
Globus Medical (GMED) combines strong fundamentals—32% revenue growth, solid profitability, and zero debt—with a technical setup hinting at a potential breakout. A growth stock worth watching.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Globus Medical (GMED) offers strong growth, solid profitability, and fair valuation, making it an ideal GARP strategy pick for investors seeking balanced returns.
Shares of medical device company Globus Medical (NYSE:GMED)
fell 6.6% in the afternoon session after the unexpected resignation of its President and CEO, Daniel Scavilla.
Hitting a new 52-week low can be a pivotal moment for any stock.
These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
Globus Medical (NYSE:GMED) is a strong growth stock with solid fundamentals and a potential technical breakout, making it a candidate for investors seeking growth opportunities in the healthcare sector.
Globus Medical (NYSE:GMED) offers strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth in the healthcare sector.
Shareholders of Globus Medical would probably like to forget the past six months even happened. The stock dropped 28.9% and now trades at $58.14. This was partly due to its softer quarterly results and might have investors contemplating their next move.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Looking back on medical devices & supplies - specialty stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Globus Medical (NYSE:GMED) and its peers.
